Skip to main content

Table 1 Patient characteristics at baseline in patients selected in the analysis and patients starting 3 or more cART in TAHOD

From: Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database

 

In analysis

In TAHOD

 

In analysis

In TAHOD

Total patients

1676

4056

Haemoglobin (g/dL) at cART initiation

Age (year) at cART initiation

  

Median (IQR)

14.0 (12.6, 15.2)

12.3 (10.8, 14.2)

Median (IQR)

36 (30, 42)

35 (30, 41)

< 10 g/dL

27 (2%)

418 (16%)

<=30

437 (26%)

1188 (29%)

10+g/dL

1248 (98%)

2250 (84%)

31~40

748 (45%)

1814 (45%)

Not tested

221

1388

41 or more

491 (29%)

1054 (26%)

CD4 count (cells/μL) at cART initiation

   

Median (IQR)

140 (42, 230)

112 (37, 209)

Gender

<=50

350 (28%)

990 (31%)

Male

1238 (74%)

2875 (71%)

51-100

155 (12%)

508 (16%)

Female

438 (26%)

1177 (29%)

101-200

328 (26%)

815 (26%)

Transgender

0 (0%)

4 (< 1%)

201-300

261 (21%)

551 (17%)

   

301 or more

161 (13%)

311 (10%)

CDC clinical classification for HIV infection at cART initiation

Not tested

421

881

Stage A

980 (58%)

1984 (50%)

HIV viral load (copies/ml) at cART initiation

Stage B

101 (6%)

407 (10%)

Median log10 (IQR)

4.93 (4.22, 5.52)

4.94 (4.32, 5.51)

Stage C

595 (36%)

1665 (41%)

< 500

101 (11%)

126 (9%)

   

501-10,000

80 (9%)

124 (9%)

Hepatitis B or C coinfection

10,001-50,000

173 (19%)

280 (20%)

No

1468 (88%)

3495 (86%)

50,001 or more

555 (61%)

885 (62%)

Yes

208 (12%)

566 (14%)

Not tested

767

2641